Patents Assigned to Ambit Biosciences Corporation
-
Publication number: 20120258081Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.Type: ApplicationFiled: May 14, 2010Publication date: October 11, 2012Applicant: AMBIT BIOSCIENCES CORPORATIONInventors: Robert E. Corringham, Patrick B. O'Donnell, Joyce K. James
-
Patent number: 8129374Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.Type: GrantFiled: August 4, 2010Date of Patent: March 6, 2012Assignee: Ambit Bioscience CorporationInventors: Shripad Bhagwat, Qi Chao, Robert M. Grotzfeld, Hitesh K. Patel, Kelly G. Sprankle
-
Patent number: 7968543Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Further, pharmaceutical formulations are provided. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.Type: GrantFiled: November 7, 2008Date of Patent: June 28, 2011Assignee: Ambit Biosciences CorporationInventors: Joyce K. James, Traci L. Savall, Shawn R. Eichelberger
-
Patent number: 7897381Abstract: The present invention provides an advance in phage display technology by permitting the uncoupling of the propagation of phages containing inserted sequences encoding heterologous polypeptides from the expression of said polypeptides. The invention provides phage constructs and methods for their use to permit phage coat protein expression, and thus phage propagation, in the absence of display of heterologous polypeptides, which may be expressed as a fusion with said coat protein in a regulated manner.Type: GrantFiled: October 31, 2007Date of Patent: March 1, 2011Assignee: Ambit Biosciences CorporationInventors: Pietro Ciceri, Patrick Parvis Zarrinkar, Daniel Kelly Treiber, David J. Lockhart
-
Patent number: 7833741Abstract: The present invention provides an advance in phage display technology by permitting the uncoupling of the propagation of phages containing inserted sequences encoding heterologous polypeptides from the expression of said polypeptides. The invention provides phage constructs and methods for their use to permit phage coat protein expression, and thus phage propagation, in the absence of display of heterologous polypeptides, which may be expressed as a fusion with said coat protein in a regulated manner.Type: GrantFiled: September 22, 2006Date of Patent: November 16, 2010Assignee: Ambit Biosciences CorporationInventors: Pietro Ciceri, Patrick Parvis Zarrinkar, Daniel Kelly Treiber, David J. Lockhart
-
Patent number: 7820657Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.Type: GrantFiled: March 16, 2007Date of Patent: October 26, 2010Assignee: Ambit Biosciences CorporationInventors: Shripad Bhagwat, Qi Chao, Robert M. Grotzfeld, Hitesh K. Patel, Kelly G. Sprankle
-
Patent number: 7767670Abstract: The invention provides methods and compositions for treating conditions mediated by various kinases wherein substituted 3-carboxamido isoxazoles compounds are employed. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects.Type: GrantFiled: November 15, 2004Date of Patent: August 3, 2010Assignee: Ambit Biosciences CorporationInventors: Shamal A. Mehta, Robert M. Grotzfeld, Zdravko V. Milanov, Andiliy G. Lai, Hitesh K. Patel, David J. Lockhart
-
Patent number: 7750160Abstract: The invention provides methods and compositions for treating conditions mediated by various kinases wherein derivatives of urea compounds are employed. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects.Type: GrantFiled: November 15, 2004Date of Patent: July 6, 2010Assignee: Ambit Biosciences CorporationInventors: Zdravko V. Milanov, Hitesh K. Patel, Robert M. Grotzfeld, Shamal A. Mehta, Andiliy G. Lai, David J. Lockhart
-
Publication number: 20090123418Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Further, pharmaceutical formulations are provided. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.Type: ApplicationFiled: November 7, 2008Publication date: May 14, 2009Applicant: Ambit Biosciences CorporationInventor: Joyce K. James
-
Publication number: 20080058219Abstract: The invention provides methods for determining the interactions between phage-displayed proteins and test molecules. The phage-displayed proteins are contacted with a reference moiety in the presence and absence of a test molecule; the behavior of the phage-displayed proteins as a function of concentration of the test molecule permits calculation of the binding affinity of the phage-displayed protein for the test molecule.Type: ApplicationFiled: August 23, 2007Publication date: March 6, 2008Applicant: Ambit Biosciences CorporationInventors: David Lockhart, Patrick Zarrinkar, Daniel Treiber
-
Patent number: 7323490Abstract: The invention provides pyrrole-containing compounds and methods of use thereof. Kits and pharmaceutical compositions comprising the pyrrole compounds of the invention are also provided. The compounds and compositions disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, and visual disorders. In particular, methods and compositions for the treatment of stroke are disclosed herein.Type: GrantFiled: May 17, 2004Date of Patent: January 29, 2008Assignee: Ambit Biosciences CorporationInventors: David J. Lockhart, Hitesh K. Patel, Zdravko V. Milanov, Shamal Anil Mehta, Patrick Parvis Zarrinkar, William H. Biggs, III, Pietro Ciceri, Miles A. Fabian, Daniel K. Treiber
-
Publication number: 20070105093Abstract: The present invention provides an advance in phage display technology by permitting the uncoupling of the propagation of phages containing inserted sequences encoding heterologous polypeptides from the expression of said polypeptides. The invention provides phage constructs and methods for their use to permit phage coat protein expression, and thus phage propagation, in the absence of display of heterologous polypeptides, which may be expressed as a fusion with said coat protein in a regulated manner.Type: ApplicationFiled: September 22, 2006Publication date: May 10, 2007Applicant: Ambit Biosciences CorporationInventors: Pietro Ciceri, Patrick Zarrinkar, Daniel Treiber, David Lockhart
-
Patent number: 7112435Abstract: The present invention provides an advance in phage display technology by permitting the uncoupling of the propagation of phages containing inserted sequences encoding heterologous polypeptides from the expression of said polypeptides. The invention provides phage constructs and methods for their use to permit phage coat protein expression, and thus phage propagation, in the absence of display of heterologous polypeptides, which may be expressed as a fusion with said coat protein in a regulated manner.Type: GrantFiled: August 7, 2002Date of Patent: September 26, 2006Assignee: Ambit Biosciences CorporationInventors: Pietro Ciceri, Patrick Parvis Zarrinkar, Daniel Kelly Treiber, David J. Lockhart
-
Publication number: 20050182125Abstract: The invention provides pyrrole-containing compounds and methods of use thereof. Kits and pharmaceutical compositions comprising the pyrrole compounds of the invention are also provided. The compounds and compositions disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, neuroinflammatory disorders, vascular disorders with an inflammatory component, and visual disorders. In particular, methods and compositions for the treatment of stroke are disclosed herein.Type: ApplicationFiled: November 15, 2004Publication date: August 18, 2005Applicant: Ambit Biosciences CorporationInventors: David Lockhart, Hitesh Patel, Zdravko Milanov, Shamal Mehta, Patrick Zarrinkar, William Biggs, Pietro Ciceri, Miles Fabian, Daniel Treiber
-
Publication number: 20050009099Abstract: The invention provides methods for determining the interactions between phage-displayed proteins and test molecules. The phage-displayed proteins are contacted with a reference moiety in the presence and absence of a test molecule; the behavior of the phage-displayed proteins as a function of concentration of the test molecule permits calculation of the binding affinity of the phage-displayed protein for the test molecule.Type: ApplicationFiled: June 21, 2004Publication date: January 13, 2005Applicant: Ambit Biosciences CorporationInventors: David Lockhart, Patrick Zarrinkar, Daniel Treiber
-
Publication number: 20040259880Abstract: The invention provides pyrrole-containing compounds and methods of use thereof. Kits and pharmaceutical compositions comprising the pyrrole compounds of the invention are also provided. The compounds and compositions disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, and visual disorders. In particular, methods and compositions for the treatment of stroke are disclosed herein.Type: ApplicationFiled: May 18, 2004Publication date: December 23, 2004Applicant: Ambit Biosciences CorporationInventors: David J. Lockhart, Hitesh K. Patel, Zdravko V. Milanov, Shamal Anil Mehta, Patrick Parvis Zarrinkar, William H. Biggs, Pietro Ciceri, Miles A. Fabian, Daniel K. Treiber
-
Publication number: 20040248972Abstract: The invention provides derivatives of statin compounds, preferably with reduced, or unappreciable, inhibitory activity against HMG-CoA reductase as well as compositions comprising such compounds. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects. Kits comprising the non-statin compounds of the invention are also provided.Type: ApplicationFiled: May 17, 2004Publication date: December 9, 2004Applicant: Ambit Biosciences CorporationInventors: David J. Lockhart, Hitesh K. Patel, Zdravko V. Milanov, Shamal Anil Mehta
-
Publication number: 20040248957Abstract: The invention provides compounds having the imidazole, oxazole, or thiazole skeleton and uses thereof. The compounds described herein bind to phosphodiesterase 6D. The compounds disclosed herein can be used to modulate the activity of phosphodiesterase 6. The invention provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects. Kits comprising the compounds of the invention are also provided.Type: ApplicationFiled: May 17, 2004Publication date: December 9, 2004Applicant: Ambit Biosciences CorporationInventors: David J. Lockhart, Hitesh K. Patel, Shamal Anil Mehta, Zdravko V. Milanov, Robert M. Grotzfeld, Andiliy G. Lai
-
Publication number: 20040242673Abstract: The invention provides compounds having the thiophene or furan skeleton and uses thereof. The invention provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects. Kits comprising the compounds of the invention are also provided. The compounds and compositions disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, and visual disorders. In particular, methods and compositions for the treatment of stroke are disclosed herein.Type: ApplicationFiled: May 17, 2004Publication date: December 2, 2004Applicant: Ambit Biosciences CorporationInventors: David J. Lockhart, Hitesh K. Patel, Shamal Anil Mehta, Zdravko V. Milanov, Robert M. Grotzfeld, Andiliy G. Lai